Polyphor's Stock Slides As Murepavadin Trials Are Halted
The Switzerland-headquartered group has suffered a setback as a couple of Phase III trials of its lead antibiotic were stopped temporarily after an unexpectedly high number of patients reported kidney injury.
You may also be interested in...
US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.
The Swiss developer of a Phase III potential first-in-class antibiotic for Pseudomonas infections plans to list on the Swiss Stock Exchange, SIX, underlining the unmet need for better drugs for nosocomial pneumonia, and also the upturn in the bourse's popularity for European IPOs.
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.